Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
  • Publication Type:
    Journal article
  • Authors:
    Várnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, Booth S, Campton NA, Collins GP, Hughes DJ, Kulasekararaj AG, Lee AJX, Olsson-Brown AC, Sharma-Oates A, Van Hemelrijck M, Lee LYW, Kerr R, Middleton G, Cazier J-B, Pugh S, Corrie P, Bedair A, Hewish M, Leonard P, Illingworth J, Hibbs S, Diamantis N, Massalha S, Fuller C, Usbourne C, Gilbert D, Davies J, Newsom-Davis T, Sharkey R, Lee R, Tivey A, Shotton R, Griffin C, Horsley L, Shamas S, Sacco JJ, Choudhury M, Noble J, Shaw H, Bolton R, Ferreira A, Hall P, Ramage P, Bhosle J, Massey A, Hill M, Mukherjee L, Ghaus A, Derby S, Brown S, Lowndes S, Dolly S, Russell B, Moss C, Muller D, Pillai A, Lowe S, Cook L, Scrase C, Jyothirmayi R, Board R, Cornthwaite S, Parikh S, Cattell E, Cox N, Gault A, Moody S, Dobeson C, Baxter M, Roques T, Pawsey A, Oakes R, Melcher L, Chan O, Ayers S, Bowyer H, Althohami M, Mittal S, Feeney L, Aujayeb A, Sheikh O, Kathirgamakarthigeyan S, Woodcock V, Holt F, Wyatt S, Topping O, Tilby M, Bhattacharyya M, Burke E, Ellis S, Chacko J, Rabbi T, Rowe M, Sargent R, Thirlwell C, Gibson J, Goldstein R, Fittall M, Gennatas S, Okines A, Best J, Tillett T, Renninson E, Grumett S, Barrington C, Pettengell R, Peng Y, Chackathayil J, Akingboye A, Hollis H, Shin Chin I, Bisht V, Hartley S, Middleton CP, Goel A, Protheroe E, Naksukpaiboon P, Anil I, Michell J, D'Costa J, Wu A, Ottaviani D, Soosaipillai G, Galazi M, Chopra N, Benafif S, Sng CCT, Wong SYN, Scott-Brown M, Copson E, Robinson T, Hudson Z, Smith F, Abdulnabi Mohamed A-A, Angelakas A, Eastlake L, Poon-King A, Brunner C, Kwan A, Maynard A, Boyce H, Spurrell E, Peck R, Kurec B
  • Publisher:
    American Medical Association (AMA)
  • Publication date:
  • Journal:
    JAMA Network Open
  • Volume:
  • Issue:
  • Article number:
  • Status:
  • Language:
  • Notes:
    This is an open access article distributed under the terms of the CC-BY License. © 2022 Várnai C et al. JAMA Network Open.
Importance: Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality. // Objective: To evaluate whether systemic anticancer treatments (SACTs), tumor subtypes, patient demographic characteristics (age and sex), and comorbidities are associated with COVID-19 mortality. // Design, Setting, and Participants: The UK Coronavirus Cancer Monitoring Project (UKCCMP) is a prospective cohort study conducted at 69 UK cancer hospitals among adult patients (≥18 years) with an active cancer and a clinical diagnosis of COVID-19. Patients registered from March 18 to August 1, 2020, were included in this analysis. // Exposures: SACT, tumor subtype, patient demographic characteristics (eg, age, sex, body mass index, race and ethnicity, smoking history), and comorbidities were investigated. // Main Outcomes and Measures: The primary end point was all-cause mortality within the primary hospitalization. // Results: Overall, 2515 of 2786 patients registered during the study period were included; 1464 (58%) were men; and the median (IQR) age was 72 (62-80) years. The mortality rate was 38% (966 patients). The data suggest an association between higher mortality in patients with hematological malignant neoplasms irrespective of recent SACT, particularly in those with acute leukemias or myelodysplastic syndrome (OR, 2.16; 95% CI, 1.30-3.60) and myeloma or plasmacytoma (OR, 1.53; 95% CI, 1.04-2.26). Lung cancer was also significantly associated with higher COVID-19–related mortality (OR, 1.58; 95% CI, 1.11-2.25). No association between higher mortality and receiving chemotherapy in the 4 weeks before COVID-19 diagnosis was observed after correcting for the crucial confounders of age, sex, and comorbidities. An association between lower mortality and receiving immunotherapy in the 4 weeks before COVID-19 diagnosis was observed (immunotherapy vs no cancer therapy: OR, 0.52; 95% CI, 0.31-0.86). // Conclusions and Relevance: The findings of this study of patients with active cancer suggest that recent SACT is not associated with inferior outcomes from COVID-19 infection. This has relevance for the care of patients with cancer requiring treatment, particularly in countries experiencing an increase in COVID-19 case numbers. Important differences in outcomes among patients with hematological and lung cancers were observed.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
There are no UCL People associated with this publication
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by